

Orthocell Presentation – HealthInvest 2025

Perth, Australia; 2 April 2025: Regenerative medicine company Orthocell Limited (ASX: OCC, “Orthocell” or the “Company”) is pleased to announce its CEO and Managing Director Mr Paul Anderson will present at the HealthInvest 2025 conference in Sydney today.

The conference is being jointly hosted by Morgans, Stockhead and IR Department to showcase emerging ASX healthcare companies to potential investors.

Mr Anderson’s presentation will provide a company overview as well as an update on the status of Orthocell’s application to the US Food and Drug Administration for 510(k) clearance for its flagship Remplir nerve repair product.

A copy of the presentation is attached.

Release authorised by:

Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General & Investor enquiries

Paul Anderson
Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
H^CK Director

P: +61 423 139 163

E: haley@hck.digital



About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG), New Zealand (WAND), UK (UKCA Mark) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.





Remplir™

Global expansion update

April 2025





Disclaimer

This presentation prepared by Orthocell Ltd (“Company”) does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations

contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.



Orthocell at a glance

Australian medical device company with growing international revenue and US market clearance of breakthrough nerve repair device pending



BEST IN CLASS PRODUCTS APPROVED IN NINE JURISDICTIONS

Bone / Striate+: US, EU, UK, AUS, NZ, CAN and SGP
Nerve / Remplir: AUS, NZ and SGP



MANUFACTURED IN AUSTRALIA

Scaled facility certified to manufacture in major jurisdictions under strict quality standards (i.e. MDSAP and MDR)



GROWING RECORD REVENUE

Third consecutive quarter of record revenue, reporting \$2.21m in the December 24 Quarter



>US\$4 Billion p.a. TAM¹

Large, under penetrated markets in bone and nerve repair alone



STRONG BALANCE SHEET, NO DEBT, NO ROYALTIES

Well-funded Company retaining all revenue benefits maximising cashflow



REMPILIR USA APPROVAL April CY25

On track to achieve US FDA 510(K) clearance and commence sales in US\$1.6 billion market

¹ Addressable markets include AUS, USA, EU/UK, SGP, CAN, BRZ, JAP & THA. Referenced papers were used to estimate procedures per annum. Papers used included both US and OUS databases and studies.



Corporate snapshot

Well-funded beyond US market clearance of Remplir, supported by leading life science institutional investors

ASX: OCC TRADING INFORMATION

Share Price (as @ 26 th March)	\$1.57
12 month low/high	\$0.35/\$0.1.79
Shares outstanding	241M
Market Capitalisation	~\$380M
Cash (26 Mch)	~\$32M
Debt (26 Mch)	Nil
Substantial Shareholders	%
Founders & Management	~11%
Institutions & HNW's (Sankofa, Cerutti, Austral Capital, Thesis Asset Mgt, Private Portfolio Mgr's, FundBPO, Wyllie Group)	~14%

12 Month Share Price and Volume



~AU\$32m


STRONG BALANCE SHEET, NO DEBT, NO ROYALTIES



Growing Revenue

Orthocell's rapid market penetration continues with a third consecutive quarter of record revenue of \$2.21 million reported in the December 24 Quarter.

Total Revenue



* US Striate and AUS Remplir sales commenced in November 2022

Key Highlights

- **US Striate+ and AUS Remplir product sales commenced in November 2022** and now ahead of expectations
- **Quarterly revenue has grown by 9%** compounded for the last nine quarters following the product launches in November 2022
- **Third consecutive quarter of record revenue**, reporting \$2.21m in the December 24 Quarter up 9% on the \$2.03 million achieved in the September 24 Quarter



Highly Credentialed Board

Appointments of John Van Der Wielen and Professor Fiona Wood AM places Orthocell in a strong position to drive its products into global markets and accelerate revenue growth



Mr John Van Der Wielen
Independent Non-Executive Chairman

- 35+ years experience in international financial services including large funds management, insurance and private banking
- Former CEO of HBF with annual revenues over \$2B
- Extensive corporate strategy, institutional and strategic investor engagement and M&A transaction experience



Mr Paul Anderson
Founder and Managing Director

- 25+ years in regenerative medicine industry
- Former MD at Verigen, successfully commercialised cartilage repair cell therapy (MACI)
- Extensive experience in product development, navigating regulatory pathways, international market launches, medical education and sales force leadership



Dr Ravi I. Thadhani
Independent Non-Executive Director

- 30 years of specialist experience working in US healthcare sector - highly regarded executive, medical administrator and researcher
- Former professor of medicine at Harvard Medical School and chief academic officer at Mass General Brigham hospital, where he oversaw a \$2.3 billion research enterprise
- Extensive US regulatory experience and commercialisation of devices and therapeutics



Professor Fiona Wood AM
Independent Non-Executive Director

- 30+ years experience as a plastic and reconstructive surgeon
- Inventor of RECELL “spray on skin” treatment, now supplied by Avita Medical Inc, a AU\$450M dual-listed company with operations in 30+ countries including the US
- Unrivalled track record in development and commercialisation of innovative regenerative medicine products




Hon Kim Beazley AC
Independent Non-Executive Director

- Unrivalled experience engaging strategic partners in the US – highly regarded politician, executive and strategic adviser
- Former Australian US Ambassador and Governor of Western Australia, Deputy Prime Minister, and Minister for both Defence and Finance
- Extensive experience representing both public and private interests for Australia



SMRT™ Manufacturing

**DEVELOPING AND MANUFACTURING
BIOLOGICAL MEDICAL DEVICES**





Collagen medical device platform

Our collagen medical device platform is comprised of a range of acellular, type 1 collagen devices for the surgical repair of bone, nerve, tendon and cartilage

BONE


Striate+™ membrane
Dental bone and tissue repair



Revenue generating in
US, EU/UK AU & CAN

NERVE

Remplir™ nerve wrap
Peripheral nerve repair



Revenue generating in
AUS, NZ & SG

TENDON

SmrtGraft™ scaffold
Tendon repair



AUS launch
CY 2025





SMRT™ manufacturing

Orthocell develops and manufactures innovative collagen medical devices that deliver the highest quality surgical repair of bone, nerve, tendon and cartilage

SMRT manufacturing process

- **Pure collagen**
Decellularization process removes all cellular and genetic material
- **Mimic human collagen**
Natural collagen structure is preserved creating the ideal environment for cellular attachment and proliferation
- **No immunogenic reaction**
70,000+ implants globally
Devices integrate and degrade commensurate with the tissue healing process





Remplir™

REDEFINING NERVE REPAIR

ortho·cell








Remplir™: Nerve repair breakthrough

Current repair methods can place delicate nerve tissue under tension, causing scarring, fibrosis and neuroma formation

1860s
Suturing



2000s
Conduits



2020s
Next generation



**Success
Rates**

50-70%


55%

85%



Remplir™: Redefining nerve repair

Collagen nerve wrap approved and reimbursed in Australia.
Intended for use in peripheral nerve repair



- ✓ Exceptional handling characteristics
- ✓ Reducing sutures
- ✓ Mimics epineurium (nerve outer layer)
- ✓ Returns nerve to pre-injured state


GUIDING PREDICTABLE
OUTCOMES IN
PERIPHERAL
NERVE REPAIR






Remplir™: indications

Remplir is the only device that can be used for either connecting severed nerves, protecting damaged nerves or capping amputated nerves



CONNECT

Trauma: motor vehicle, power tool, surgical injuries, sports and military related accidents



PROTECT

Compression: blunt trauma, revisions surgeries (e.g. carpal/cubital tunnel)



CAP

Amputation: amputations, stump neuroma, mastectomies, schwannoma




Remplir™: compelling clinical results

Patients regained voluntary muscle movement within 12 months, increasing strength and range of motion at 24 months



We are now seeing a consistent return of arm and hand function following nerve transfer surgery with Remplir. Remplir is increasing the success rate and efficiency of nerve transfer surgery.

- Leading Australian orthopaedic nerve specialist and clinical trial lead, Dr Alex O'Beirne



Useful Function

Voluntary movement with improved strength and range of motion

Minimal Function

Voluntary movement restored, limited strength and range of movement

No Function

No voluntary movement

FINAL RESULTS

85% (23 of 27) of nerve repairs resulted in functional recovery of muscles controlled by the repaired nerve



Australian Remplir™ case study opens up global nerve repair opportunity

Injury

- Mountain bike accident
- C5 quadriplegia

Impact

- No arm strength and no movement in fingers and thumbs
- Life in a wheelchair was difficult

Surgery

- Nerve transfer using Remplir™

Outcome

- Better fine motor control and can do things with two hands
- Playing wheelchair rugby and driving his car



Remplir™ patient:
Adrian Walsh

This treatment has made a world of difference to me.
The increased strength and mobility in my arm and hand has really boosted my independence. I am contributing more around the home and can help my wife and kids – it feels good.

- Adrian Walsh, Remplir™ patient






Successful launch with growing revenue

AUS commercial launch¹ of Remplir with Device Technologies, reimbursed in the private healthcare system in November 2022, with sales unit volumes exceeding expectations

Remplir product revenue since AUS market launch



- **127% growth in Remplir revenue from \$457K in FY23 to \$1.04M in FY24**
- **Product sales to Device Technology significantly exceeding guidance** – over 180 orthopaedic and plastic reconstructive surgeons
- **First major international regulatory approval** - appointment of an exclusive distributor and achievement of first sales in the key market of Singapore
- **Adoption drivers** - enables less suturing, creation of the optimal healing microenvironment and facilitation of free gliding within the repair site during the critical healing period

1. Orthocell supplies Device Technologies (DVT) with Remplir products, and DVT exclusively market and distribute Remplir in Australia.




US FDA APPROVAL EXPECTED MARCH / APRIL CY25 TO US\$1.6 BILLION MARKET



Over 700,000¹ peripheral nerve repair procedures in the US per year, 90% undertaken using suture only method.

- **Successfully completed the 510(k) Regulatory study**, meeting all endpoints and providing key data required to support December 24 marketing submission
- **US market clearance anticipated in April 2025** immediately followed by sales
- **Current devices are not widely adopted** due to suboptimal outcomes – Axogen, Integra and Stryker collectively sell ~70k units per year (10% of procedures)

Annual US nerve reconstructions



1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both US and OUS databases and studies



US Sales and Medical Affairs Executives

Orthocell has appointed two experienced US-based executives, John Walker and Phillip Edmondson, to drive the market launch and sales of Remplir following the expected US FDA market clearance in March / April 2025



John Walker

Vice President – Sales

Mr Walker is a highly experienced sales executive, who has successfully led global product launches and sales strategies, most notably helping to lead the growth of nerve repair device sales at Axogen.



Phillip Edmondson

Vice President – Medical Affairs

Mr Edmondson is an award-winning medical affairs professional, who excels in creating product awareness, building advocacy and implementing successful medical education programs that contribute to sales growth.



Remplir™: Path to partnering

Orthocell is underpinned by a proven business model for innovating, developing, launching and successfully partnering medical device products

Scale Organisation	US Approval	Brand Ambassadors	Data Package	Sales and Marketing
<ul style="list-style-type: none">✓ Executive team✓ Manufacturing facility✓ Quality system✓ Third party logistics✓ Organisational team○ ERP implementation○ Hire in-country team	<ul style="list-style-type: none">✓ Pilot study✓ Pre-submission meeting✓ Animal surgeries✓ In-life assessments✓ Data analysis✓ 510k submission	<ul style="list-style-type: none">✓ Scientific narrative✓ KOL panel design✓ KOL engagement strategy✓ In-country collaboration✓ Centres of excellence✓ Clinician advocacy program	<ul style="list-style-type: none">✓ Published preclinical✓ Published clinical✓ TGA approval○ PMCF○ In country study	<ul style="list-style-type: none">✓ Positioning strategy✓ Pricing strategy✓ Customer segmentation✓ Promotion plan✓ Launch collateral✓ Medical education program○ US team training material○ Engage distributors○ Establish key accounts



Remplir™: Pre-launch completed

Orthocell successfully completed a pre-launch program at the 2025 IFSSH and IFSHT Triennial Congress in the US in advance of FDA approval. Attended by leading peripheral nerve surgeons from the US and other countries.

2025 IFSSH and IFSHT Triennial Congress
WASHINGTON, D.C. USA



2025 IFSSH and IFSHT Triennial Congress

International Federation of Societies for Surgery of the Hand
International Federation of Societies for Hand Therapy







Remplir™: Large addressable market in nerve reconstruction

Remplir is a breakthrough product on track to be the global market leader in peripheral nerve repair – a retail market estimated to exceed US\$3.5 billion¹ per annum


Total Addressable Retail Market (US\$m)



Est. procedures p.a. at peak ('000)



■ AU/NZ ■ USA ■ EU/UK ■ SGP ■ CAN ■ BRZ ■ JAP ■ THA



Targeting a 20% share of the US\$3.5 billion total addressable retail market

1. Addressable markets include AUS, USA, EU/UK, SGP, CAN, BRZ, JAP, THA. Referenced papers were used to estimate procedures per annum. Papers used included both US and OUS databases and studies



Remplir™: Market Expansion

Regulatory approval for Remplir in Singapore achieved in 2H CY24 with a further four applications planned in EU, UK & Brazil in the next 6-12 months

APPROVED in Australia, New Zealand and Singapore									
REGULATORY APPLICATIONS	2024	2025				2026			
	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
USA	Submitted	Expected Approval							
Canada		Submitted							Expected Approval
Thailand		Submitted		Expected Approval					
EU + UK				Planned Submission					Expected Approval
Brazil					Planned Submission				Expected Approval



Upcoming catalysts¹

Remplir – redefining nerve repair

US FDA market clearance

2Q CY25

Appoint US sales team

2Q CY25

Appoint US distributors

2Q CY25

US first sales

2Q CY25

EU+UK & Brazil submissions lodged

3Q / 4Q CY25

Striate+ – growing better bone

Germany, Austria, Switzerland market launch

Achieved

Singapore product registration

Achieved

Brazil product registration

2Q CY25

Columbia submission lodged

2Q CY25

1. Timelines may be subject to change due to circumstances not under the Company's control



Key Investment Highlights



Commercial-stage
medical device
company at revenue
inflection point



Best in class
products for Bone,
Nerve and Tendon
repair



**Strengthened
board** with the
appointments of
highly experienced
executives John Van
Der Wielen, Professor
Fiona Wood and Kim
Beazley



**~\$32M cash at bank,
strengthened
register, no royalty
liabilities and
funded to US
approval** of
breakthrough nerve
repair device



**Near term value
drivers** including
Remplir US 510(k)
market clearance
April CY25



Authorised for release by:

Co-Founder and Managing Director, Paul Anderson

Orthocell Limited P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

orthocell.com

